Cullinan Therapeutics Inc (NASDAQ:CGEM)’s traded shares stood at 0.51 million during the last session, with the company’s beta value hitting -0.10. At the close of trading, the stock’s price was $17.95, to imply an increase of 1.87% or $0.33 in intraday trading. The CGEM share’s 52-week high remains $30.19, putting it -68.19% down since that peak but still an impressive 57.44% since price per share fell to its 52-week low of $7.64. The company has a valuation of $1.04B, with an average of 0.51 million shares in intraday trading volume over the past 10 days and average of 781.06K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Cullinan Therapeutics Inc (CGEM), translating to a mean rating of 1.00. Of 4 analyst(s) looking at the stock, 0 analyst(s) give CGEM a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.81.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cullinan Therapeutics Inc (NASDAQ:CGEM) trade information
After registering a 1.87% upside in the last session, Cullinan Therapeutics Inc (CGEM) has traded red over the past five days. The 5-day price performance for the stock is -0.17%, and 10.53% over 30 days. With these gigs, the year-to-date price performance is 76.15%. Short interest in Cullinan Therapeutics Inc (NASDAQ:CGEM) saw shorts transact 8.05 million shares and set a 13.17 days time to cover.
The extremes give us $28 and $38 for target low and target high price respectively. As such, CGEM has been trading -111.7% off suggested target high and -55.99% from its likely low.
Cullinan Therapeutics Inc (CGEM) estimates and forecasts
Looking at statistics comparing Cullinan Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Cullinan Therapeutics Inc (CGEM) shares are 6.15% up over the last 6 months, with its year-to-date growth rate lower than industry average at 13.28% against 17.20%. Revenue is forecast to grow 11.00% this quarter before falling -53.70% for the next one.
CGEM Dividends
Cullinan Therapeutics Inc has its next earnings report out on 2024-Nov-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Cullinan Therapeutics Inc (NASDAQ:CGEM)’s Major holders
Cullinan Therapeutics Inc insiders hold 4.51% of total outstanding shares, with institutional holders owning 115.25% of the shares at 120.70% float percentage. In total, 115.25% institutions holds shares in the company, led by BIOIMPACT CAPITAL LLC. As of 2024-06-30, the company held over 7.65 million shares (or 17.7821% of shares), all amounting to roughly $133.39 million.
The next major institution holding the largest number of shares is BVF INC/IL with 5.75 million shares, or about 13.3703% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $100.29 million.
We also have Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF as the top two Mutual Funds with the largest holdings of the Cullinan Therapeutics Inc (CGEM) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 1.5 shares. This is just over 2.59% of the total shares, with a market valuation of $26.93 million. Data from the same date shows that the other fund manager holds a little less at 1.12, or 1.92% of the shares, all valued at about 20.02 million.
